Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 2144 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
LETTER TO THE EDITOR
Year : 2016  |  Volume : 20  |  Issue : 3  |  Page : 413-414

HbA1c for diabetes screening in acute coronary syndrome: National Institute for Health and Care Excellence criteria and universal screening


1 Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Tropical Medicine Unit, Hainan Medical University, Hainan, China

Date of Web Publication11-Apr-2016

Correspondence Address:
Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.179989

Rights and Permissions

How to cite this article:
Joob B, Wiwanitkit V. HbA1c for diabetes screening in acute coronary syndrome: National Institute for Health and Care Excellence criteria and universal screening. Indian J Endocr Metab 2016;20:413-4

How to cite this URL:
Joob B, Wiwanitkit V. HbA1c for diabetes screening in acute coronary syndrome: National Institute for Health and Care Excellence criteria and universal screening. Indian J Endocr Metab [serial online] 2016 [cited 2019 Nov 12];20:413-4. Available from: http://www.ijem.in/text.asp?2016/20/3/413/179989

Sir,

Diabetes mellitus (DM) is the global public health threat. The early detection for DM by screening is accepted as effective secondary prevention. For the patients with acute coronary syndrome (ACS), the screening is proved to be useful. The screening is recommended by National Institute for Health and Care Excellence (NICE) criteria.[1] NICE guidelines noted that all ACS patients with admission blood glucose concentrations above 11.0 mmol/l should have a fasting plasma glucose determination no earlier than day 4 after onset or have an HbA1c test before discharge.[2],[3]” The coverage and cost of the screening alternative are the big concern. McCune et al. mentioned that the universal coverage screening can be cost effective.[3] However, the concern on the coverage is still the issue to be investigated. Based on the previous report by McCune et al., using NICE criteria, 1 from 7 cases accepted for further screening whereas 26 from 49 cases accepted universal screening.[3] Based on this information, it can also confirm that the coverage of universal screening is better than the practice based on NICE criteria. Hence, it is confirmed that universal coverage screening for DM must be implemented for any ACS patients.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Edge JA, Swift PG, Anderson W, Turner B; Youth and Family Advisory Committee of Diabetes UK. Diabetes services in the UK: Fourth national survey; are we meeting NSF standards and NICE guidelines? Arch Dis Child 2005;90:1005-9.  Back to cited text no. 1
    
2.
NICE Clinical Guideline; CG130. Hyperglycaemia in Acute Coronary Syndromes: Management of Hyperglycaemia in Acute Coronary Syndromes. London: National Institute for Health and Care Excellence; 2013. Available from: http://www.guidance.nice.org.uk/CG130. [Last accessed on 2015 Dec 20] .  Back to cited text no. 2
    
3.
McCune C, Maynard S, McClements B, Lindsay JR. HbA1c for diabetes screening in acute coronary syndrome: Time for a reappraisal of the guidelines? Ulster Med J 2015;84:154-6.  Back to cited text no. 3
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
 References

 Article Access Statistics
    Viewed593    
    Printed4    
    Emailed0    
    PDF Downloaded169    
    Comments [Add]    

Recommend this journal